128 related articles for article (PubMed ID: 3264035)
21. Brain SPECT in Wilson's disease.
Watanabe N; Seto H; Shimizu M; Kageyama M; Morijiri M; Nomura K; Wu YW; Kakishita M
Clin Nucl Med; 1995 Nov; 20(11):1029-30. PubMed ID: 8565366
[No Abstract] [Full Text] [Related]
22. Comparison of clinical types of Wilson's disease and glucose metabolism in extrapyramidal motor brain regions.
Hermann W; Barthel H; Hesse S; Grahmann F; Kühn HJ; Wagner A; Villmann T
J Neurol; 2002 Jul; 249(7):896-901. PubMed ID: 12140675
[TBL] [Abstract][Full Text] [Related]
23. Wilson's disease studied with FDG and positron emission tomography.
Hawkins RA; Mazziotta JC; Phelps ME
Neurology; 1987 Nov; 37(11):1707-11. PubMed ID: 3499583
[TBL] [Abstract][Full Text] [Related]
24. Computed tomography in Wilson's disease.
Selekler K; Kansu T; Zileli T
Arch Neurol; 1981 Nov; 38(11):727-8. PubMed ID: 7305706
[TBL] [Abstract][Full Text] [Related]
25. Wilson's disease: MRI demonstration of cavitations in basal ganglia and thalami.
Sener RN
Pediatr Radiol; 1993; 23(2):157. PubMed ID: 8516046
[TBL] [Abstract][Full Text] [Related]
26. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
Tatsch K; Schwarz J; Oertel WH; Kirsch CM
Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
[TBL] [Abstract][Full Text] [Related]
27. CT hypodensity on cerebral white matter in Wilson's disease.
Jardim LB; Carneiro A; Hansel S; Rieder CR; Giugliani R
Arq Neuropsiquiatr; 1991 Jun; 49(2):211-4. PubMed ID: 1810242
[TBL] [Abstract][Full Text] [Related]
28. Morphological and functional imaging in neurological and non-neurological Wilson's patients.
Hermann W
Ann N Y Acad Sci; 2014 May; 1315():24-9. PubMed ID: 24495036
[TBL] [Abstract][Full Text] [Related]
29. Extrapyramidal symptoms in Wilson's disease are associated with olfactory dysfunction.
Mueller A; Reuner U; Landis B; Kitzler H; Reichmann H; Hummel T
Mov Disord; 2006 Sep; 21(9):1311-6. PubMed ID: 16763975
[TBL] [Abstract][Full Text] [Related]
30. Comparison of technetium-99m-ECD to Xenon-133 SPECT in normal controls and in patients with mild to moderate regional cerebral blood flow abnormalities.
Devous MD; Payne JK; Lowe JL; Leroy RF
J Nucl Med; 1993 May; 34(5):754-61. PubMed ID: 8478707
[TBL] [Abstract][Full Text] [Related]
31. Wilson's disease: evoked potentials and computed tomography.
Roach ES; Ford CS; Spudis EV; Riela AR; McLean WT; Gilliam J; Ball MR
J Neurol; 1985; 232(1):20-3. PubMed ID: 3998770
[TBL] [Abstract][Full Text] [Related]
32. Brain single photon emission computed tomography: newer activation and intervention studies.
Tikofsky RS; Hellman RS
Semin Nucl Med; 1991 Jan; 21(1):40-57. PubMed ID: 1996427
[TBL] [Abstract][Full Text] [Related]
33. [A problem of quantitative measurement of regional cerebral blood flow using microsphere model and N-isopropyl-p-[123I]iodoamphetamine (IMP): comparison with 133Xe SPECT and sequential dynamic 123I-IMP SPECT].
Takahashi N; Ohkubo M; Odano I; Ohtaki H; Noguchi E; Yamazaki Y; Hatano M; Sakai K
Kaku Igaku; 1994 Apr; 31(4):319-26. PubMed ID: 8196228
[TBL] [Abstract][Full Text] [Related]
34. [A case of Wilson's disease with a high density lesion in hepatic computerized tomography scan and abnormal secretion of pituitary hormones].
Kikuchi A; Matsui T; Kodama K; Minamidani N; Fukami T; Chihara K; Fujita T
Nihon Naika Gakkai Zasshi; 1984 Oct; 73(10):1512-8. PubMed ID: 6520516
[No Abstract] [Full Text] [Related]
35. Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.
Leggio L; Ferrulli A; Mirijello A; Abenavoli L; Di Giuda D; Funiciello S; Rotoli M; Gasbarrini G; Addolorato G
Int J Immunopathol Pharmacol; 2007; 20(1):185-90. PubMed ID: 17346443
[TBL] [Abstract][Full Text] [Related]
36. A multicenter validation of regional cerebral blood flow quantitation using [123I]iodoamphetamine and single photon emission computed tomography.
Iida H; Akutsu T; Endo K; Fukuda H; Inoue T; Ito H; Koga S; Komatani A; Kuwabara Y; Momose T; Nishizawa S; Odano I; Ohkubo M; Sasaki Y; Suzuki H; Tanada S; Toyama H; Yonekura Y; Yoshida T; Uemura K
J Cereb Blood Flow Metab; 1996 Sep; 16(5):781-93. PubMed ID: 8784223
[TBL] [Abstract][Full Text] [Related]
37. Relationship between striatal glucose consumption and copper excretion in patients with Wilson's disease treated with D-penicillamine.
Hefter H; Kuwert T; Herzog H; Arendt G; Stremmel W; Feinendegen LE
J Neurol; 1993 Nov; 241(1):49-53. PubMed ID: 8138822
[TBL] [Abstract][Full Text] [Related]
38. Effect of D-penicillamine treatment on brain metabolism in Wilson's disease: a case study.
De Volder A; Sindic CJ; Goffinet AM
J Neurol Neurosurg Psychiatry; 1988 Jul; 51(7):947-9. PubMed ID: 3264567
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of regional cerebral blood flow using 99mTc-ECD SPECT in ethanol dependent patients: pilot study].
Pach D; Hubalewska-Dydejczyk A; Szurkowska M; Kamenczak A; Targosz D; Gawlikowski T; Huszno B; Głowa B
Przegl Lek; 2007; 64(4-5):204-7. PubMed ID: 17724867
[TBL] [Abstract][Full Text] [Related]
40. [Correlation of regional cerebral blood flow between Xe-CT and 133Xe-SPECT: validity of Xe-CT in evaluating rCBF].
Haku T; Hosoya T; Komatani A; Watanabe N; Yamaguchi K
Nihon Igaku Hoshasen Gakkai Zasshi; 1996 Oct; 56(12):828-33. PubMed ID: 8940812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
